Imuldosa, a Stelara biosimilar, is approved for autoimmune diseases, marking the fifth ustekinumab biosimilar in the US market. Stelara, a top-grossing biologic, underwent CMS price negotiations with ...

Credit: Celltrion Steqeyma, formerly known as CT-P43, is a human interleukin-12 and -23 antagonist. According to Celltrion, Steqeyma is expected to be available in February 2025. The Food and Drug ...

SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the ...

Stelara (ustekinumab) is a prescription drug that’s used to treat certain autoimmune conditions, such as plaque psoriasis. It’s not known whether Stelara is safe to receive during pregnancy or while ...

Alvotech and Teva Pharmaceuticals have received approval from the Food and Drug Administration for Selarsdi (ustekinumab-aekn) injection as a biosimilar to Janssen's Stelara. Designed for subcutaneous ...

Please provide your email address to receive an email when new articles are posted on . Selarsdi is approved for the treatment of plaque psoriasis, psoriatic arthritis in adults, patients aged 6 years ...

Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitis The FDA previously approved ...

Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...

DNA methylation biomarkers predicted response to vedolizumab and ustekinumab in patients with Crohn's disease. Prediction models outperformed existing tools for vedolizumab and ustekinumab, especially ...